[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342772-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-342772-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","homologous-recombination-repair-deficiency-in-metastatic-prostate-cancer-new-therapeutic-opportunities-narrative-review","Homologous Recombination Repair Deficiency in Metastatic Prostate Cancer - New Therapeutic Opportunities - narrative review","","More than 20% of metastatic prostate cancer involves genomic defects in DNA damage repair pathways, predominantly within homologous recombination repair-related genes. Following approval of olaparib, PARP inhibitors enable precision medicine for patients whose tumors harbor BRCA1 or BRCA2 pathogenic/likely pathogenic variants, yet multiple clinical and biological questions remain. This narrative review links homologous recombination repair deficiency to prostate cancer, summarizes methods to assess homologous recombination repair status, and details cross-talk with the androgen receptor pathway. It also reviews evidence for PARP inhibitor activity in both deficient and proficient tumors and outlines emerging resistance mechanisms, including the rationale for combination strategies using PARP inhibitors.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/homologous-recombination-repair-deficiency-in-metastatic-prostate-cancer-new-therapeutic-opportunities-narrative-review/342772/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/homologous-recombination-repair-deficiency-in-metastatic-prostate-cancer-new-therapeutic-opportunities-narrative-review/342772.png","ImageObject",300,407,{"name":42,"@type":43},"Eliana","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-12","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What proportion of metastatic prostate cancer cases involve DNA damage repair defects?","Question",{"text":63,"@type":64},"More than 20% of metastatic prostate cancer carries genomic defects involving DNA damage repair pathways, mainly in homologous recombination repair-related genes.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does olaparib influence treatment for patients with homologous recombination repair deficiency?",{"text":68,"@type":64},"Recent approval of olaparib enables precision medicine using PARP inhibitors for metastatic prostate cancer in this subset, especially for BRCA1 or BRCA2 pathogenic/likely pathogenic variants.",{"name":70,"@type":61,"acceptedAnswer":71},"What does the review cover regarding homologous recombination repair and prostate cancer?",{"text":72,"@type":64},"It describes the relationship between homologous recombination repair deficiency and prostate cancer, methods to determine homologous recombination repair status, and the cross-talk between homologous recombination repair and the androgen receptor pathway.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},342772,1790323833,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":109,"preview_page_count":33,"preview_urls":146},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","Review  \nHomologous Recombination Repair Deficiency in Metastatic Prostate Cancer: New Therapeutic Opportunities  \nClaudia Piombino 1,†, Stefania Pipitone 1,†, Elena Tonni 1, Luciana Mastrodomenico 1, Marco Oltrecolli 1, Cyrielle Tchawa 1, Rossana Matranga 1, Sara Roccabruna 1, Elisa D’Agostino 1, Marta Pirola 1, Francesca Bacchelli 2, Cinzia Baldessari 1, Maria Cristina Baschieri 3, Massimo Dominici 1,3, Roberto Sabbatini 1  \nand Maria Giuseppa Vitale 1, *  \nCitation: Piombino, C.; Pipitone, S.; Tonni, E.; Mastrodomenico, L.; Oltrecolli, M.; Tchawa, C.; Matranga, R.; Roccabruna, S.; D’Agostino, E.; Pirola, M.; et al. Homologous Recombination Repair Deficiency in Metastatic Prostate Cancer: New Therapeutic Opportunities. Int. J. Mol. Sci. 2024, 25, 4624. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/ijms25094624](10.3390/ijms25094624)  \nAcademic Editor: Yaser Gamallat  \nReceived: 25 March 2024  \nRevised: 14 April 2024  \nAccepted: 22 April 2024  \nPublished: 24 April 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena,  \n41124 Modena, Italy; [256171@studenti.unimore.it](256171@studenti.unimore.it) (C.P.); [pipitone.stefania@aou.mo.it](pipitone.stefania@aou.mo.it) (S.P.); [325770@studenti.unimore.it](325770@studenti.unimore.it) (E.T.); [297001@studenti.unimore.it](297001@studenti.unimore.it) (L.M.); [297143@studenti.unimore.it](297143@studenti.unimore.it) (M.O.); [308106@studenti.unimore.it](308106@studenti.unimore.it) (C.T.); [297415@studenti.unimore.it](297415@studenti.unimore.it) (R.M.); [279224@studenti.unimore.it](279224@studenti.unimore.it) (S.R.); [297407@studenti.unimore.it](297407@studenti.unimore.it) (E.D.); [310546@studenti.unimore.it](310546@studenti.unimore.it) (M.P.); [baldessari.cinzia@aou.mo.it](baldessari.cinzia@aou.mo.it) (C.B.); [massimo.dominici@unimore.it](massimo.dominici@unimore.it) (M.D.); [sabbrob@unimore.it](sabbrob@unimore.it) (R.S.)  \n2 Clinical Trials Office, Division of Oncology, Department of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio Emilia, 41124 Modena, Italy; [francesca.bacchelli@unimore.it](francesca.bacchelli@unimore.it)  \n3 Laboratory of Cellular Therapy, Division of Oncology, Department of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio Emilia, 41124 Modena, Italy; [mariacristina.baschieri@unimore.it](mariacristina.baschieri@unimore.it)  \n* [Correspondence: vitale.mariagiuseppa@aou.mo.it](Correspondence: vitale.mariagiuseppa@aou.mo.it)[ ](Correspondence: vitale.mariagiuseppa@aou.mo.it)† These authors contributed equally to this work.  \nAbstract: More than 20% of metastatic prostate cancer carries genomic defects involving DNA damage repair pathways, mainly in homologous recombination repair-related genes. The recent approval of olaparib has paved the way to precision medicine for the treatment of metastatic prostate cancer with PARP inhibitors in this subset of patients, especially in the case of BRCA1 or BRCA2 pathogenic/likely pathogenic variants. In face of this new therapeutic opportunity, many issues remain unsolved. This narrative review aims to describe the relationship between homologous recombination repair deficiency and prostate cancer, the techniques used to determine homologous recombination repair status in prostate cancer, the crosstalk between homologous recombination repair and the androgen receptor pathway, the current evidence on PARP inhibitors activity in metastatic prostate cancer also in homologous recombination repair-proficient tumors, as well as emerging mechanisms of ","cbCaikLTDNtpo59c","https://ap.wps.com/l/cbCaikLTDNtpo59c","pdf",1224801,16,"English","# Introduction\n# Abstract\n# Keywords\n# Metastatic prostate cancer and genomic defects\n# Homologous recombination repair status and clinical implications\n# PARP inhibitor activity and resistance mechanisms","[{\"question\":\"What proportion of metastatic prostate cancer cases involve DNA damage repair defects?\",\"answer\":\"More than 20% of metastatic prostate cancer carries genomic defects involving DNA damage repair pathways, mainly in homologous recombination repair-related genes.\"},{\"question\":\"How does olaparib influence treatment for patients with homologous recombination repair deficiency?\",\"answer\":\"Recent approval of olaparib enables precision medicine using PARP inhibitors for metastatic prostate cancer in this subset, especially for BRCA1 or BRCA2 pathogenic/likely pathogenic variants.\"},{\"question\":\"What does the review cover regarding homologous recombination repair and prostate cancer?\",\"answer\":\"It describes the relationship between homologous recombination repair deficiency and prostate cancer, methods to determine homologous recombination repair status, and the cross-talk between homologous recombination repair and the androgen receptor pathway.\"}]","Homologous Recombination Repair Deficiency in Metastatic Prostate Cancer - New Therapeutic Opportunities - narrative review | PDF",1790048182,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c1a02472e7e208be57ff0c89bf4df3d5.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2b41f99475d73f042c4e2d3e82275ced.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/87484fda4aa0c3b12ac7000847f503bc.webp",981,693,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a001694bb23a44f915ac8f71f7ab6aa5.webp",980,692]